Humoral response to mRNA‐based COVID‐19 vaccine in patients with myeloid malignancies

Data on the response to the COVID‐19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2022-06, Vol.197 (6), p.691-696
Main Authors: Mori, Akio, Onozawa, Masahiro, Tsukamoto, Shihori, Ishio, Takashi, Yokoyama, Emi, Izumiyama, Koh, Saito, Makoto, Muraki, Haruna, Morioka, Masanobu, Teshima, Takanori, Kondo, Takeshi
Format: Article
Language:English
Subjects:
acute myeloid leukaemia
Acute myeloid leukemia
COVID-19
Hematology
humoral response
Immune response (humoral)
Malignancy
mRNA
Myelodysplastic syndrome
Original Paper
Patients
SARS‐CoV‐2 vaccine
Seroconversion
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Data on the response to the COVID‐19 vaccine in patients with myeloid malignancy, who are at severe risk in case of infection, have not emerged. In a study of 69 patients with myeloid malignancies, including 46 patients with acute myeloid leukaemia (AML) and 23 patients with myelodysplastic syndrome (MDS), anti‐spike SARS‐CoV‐2 antibody titres were measured 3 months after the second mRNA‐based vaccination. Seroconversion rates for AML and MDS were 94.7% and 100% respectively, with no significant difference from healthy controls (HCs). Patients with MDS showed a significantly lower antibody titre than that in HCs or AML patients. In AML patients, the antibody titres were comparable to those in HCs when treatment was completed, but lower in patients under maintenance therapy. The response to COVID‐19 vaccine appears to be related to disease and treatment status. Patients with myeloid malignancies may be more responsive to vaccines than patients with lymphoid malignancies.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18138